Bioequivalence studies of ritonavir/lopinavir and favipravir molecules have been successfully completed in Farmagen, which is the only BE & BA clinical center that can still actively work with isolation procedure due to COVID-19 pandemic in our country and one of the few centers in the world. Bioanalytical studies have been carried out at Novagenix Bioanalytical R&D Center without interruption and continues by competing against time. In this way, it will be possible to supply these drugs, which have problems in their supply and have high costs, very cheaply.
The umifenovir tablet bioequivalence study will begin in a very short time and the favipravir equivalent candidates developed by our other domestic manufacturers are waiting in line.
Thank you to our partners and the officials who did not withhold their support.